上海美悦生物科技发展有限公司

Shanghai Meiyue Biological Technology Development (Meiyue Biotech) is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative small molecule targeted therapies. Founded in 2016, the company focuses on addressing unmet medical needs in oncology, particularly by developing next-generation inhibitors that overcome drug resistance in lung cancer. Its lead candidate, MY-001, is a fourth-generation EGFR inhibitor designed to target the C797S mutation, which often causes resistance to third-generation treatments. Another key program, MY-008, is a multi-target inhibitor for ALK and ROS1 rearrangements. Meiyue Biotech operates an integrated R&D platform and has received backing from prominent venture capital firms like Qiming Venture Partners and TF Capital. The company is actively advancing its pipeline through clinical trials in China to provide more effective treatment options for cancer patients.